Therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1320-1327

  Kootstra Ros, Jenny E ^a,e   Van Weelden, Marga J M ^b   Hinrichs, John W J ^a,b   De Smet, Peter A G M ^c,d   Van Der Weide, Jan ^a,b  

^a ST JANSDAL HOSPITAL   (Netherlands)

^b Psychiatric Hospital Meerkanten   (Netherlands)

^c Scientific Institute Dutch Pharmacists   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Hospital Group Twente   (Netherlands)

Author keywords

Antidepressant; Cytochrome P450; Genetic polymorphism; Primary care

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; FLUOXETINE; FLUVOXAMINE; NORCLOMIPRAMINE; PAROXETINE; PROTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME POLYMORPHISM; GENERAL PRACTICE; GENOTYPE; HUMAN; PRESCRIPTION; PRIMARY MEDICAL CARE; STEADY STATE; TREATMENT REFUSAL;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33749873354     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293754     Document Type: Article

References (42)

1. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39:127-153.
2. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071-1088.
3. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78.
4. van der Weide J, Steijns LSW, van Weelden MJM. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13:169-172.
5. Brøsen K, De Morais SMF, Meyer UA, et al. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995;5:312-317.
6. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 2003;49:542-551.
7. Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;51:12-17.
8. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8:15-26.
9. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit. 2005;27:478-483.
10. http://medicine.iupui.edu/flockhart
11. Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59:5-12.
12. De Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
13. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 1990;347:773-776.
14. Hersberger M, Marti-Jaun J, Rentsch K, et al. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetraprimer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem. 2000;46:1072-1077.
15. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990;265:17209-17214.
16. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226:327-338.
17. Hersberger M, Marti-Jaun J, Rentsch K, et al. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem. 2001;47:772-774.
18. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37:147-165.
19. Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36:98-104.
20. Lundmark J, Bengtsson F, Nordin J, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354-359.
21. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological teratment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:5-43.
22. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469.
23. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154.
24. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
25. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
26. Eap CB, Sirot EJ, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. Ther Drug Monit. 2004;26:152-155.
27. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997;25:740-744.
28. Kristoffersen L, Bugge A, Lundanes E, et al. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-preformance liquid chromatography with ultraviolet and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1999;734:229-246.
29. Palego L, Marazziti D, Biondi L, et al. Simultaneous plasma level analysis of clomipramine, N-desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography. Ther Drug Monit. 2000;22:190-194.
30. Hicks DR, Wolaniuk D, Russell A, et al. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit. 1994;16:100-107.
31. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
32. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342-349.
33. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155-163.
34. Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001;70:327-335.
35. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31:347-353.
36. Zourkova A, Hadasova E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys. 2003;22:103-113.
37. Cramer JA, Rosenheck R. Compliance with medication regiments for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
38. Gaedigk A, Ryder DL, Bradford LD, et al. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promotor polymorphism. Clin Chem. 2003;49:1008-1011.
39. Raimundo S, Fischer J, Eichelbaum M, et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000;10:577-581.
40. Steimer W, Zöpf K, Von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50:1623-1633.
41. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
42. Veefkind AH, Commenee JCL, Broekema WJ. Serumspiegels van psychofarmaca. Tijdschrift voor Psychiatrie. 1993;35:242-253.